Advances in drug development for acute migraine

Drugs

Volumn 72, Issue 17, 2012, Pages 2187-2205

  Cady, Ryan J ^a   Shade, Candace L ^b   Cady, Roger K ^b  

^a MISSOURI STATE UNIVERSITY   (United States)

^b Banyan Group Inc   (United States)

Author keywords

Antimigraines; AP 1531; BI 44370; Calcitonin gene related peptide receptor Antagonists; CJ 023423; Cyclooxygenase inhibitors; Diclofenac potassium; Dihydroergotamine mesilate; Eletriptan; Feverfew ginger; Filorexant; Intramuscular; Intranasal; Intravenous; Ketorolac; Lasmiditan; Lavoltidine; LY 334370; Migraine; Nitric oxide; Nonsteroidal Anti inflammatories; Oral; PNU 142633F; Prostaglandins; Rizatriptan; Rofecoxib; Serotonin; Serotonin receptor Agonists; Subcutaneous; Sublingual; Sumatriptan; Telcagepant; Tezampanel; Trometamol; Tryptamines; Valproate semisodium.

Indexed keywords

1 [2 [4 (4 CARBAMOYLPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANTICONVULSIVE AGENT; AURALGAN; BOTULINUM TOXIN A; CALCITONIN; DICLOFENAC POTASSIUM; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; EXCEDRIN; FROVATRIPTAN; IBUPROFEN; KETOROLAC; LASMIDITAN; NAPROXEN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OREXIN; RIZATRIPTAN; ROX 188; SUMATRIPTAN; TELCAGEPANT; TEZAMPANEL; TRIPTAN DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; ZOLMITRIPTAN;

ACUTE DISEASE; ALLERGIC REACTION; ANALGESIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); DIZZINESS; DRUG CLASSIFICATION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; DRUG TOLERABILITY; EPISODIC MIGRAINE; EXCITABILITY; FATIGUE; GENE MUTATION; GENETIC PREDISPOSITION; HEADACHE; HUMAN; MIGRAINE; PERIPHERAL NERVOUS SYSTEM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHONOPHOBIA; PHOTOPHOBIA; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VERTIGO;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DISABILITY EVALUATION; DRUG DISCOVERY; ERGOTAMINES; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN RECEPTOR AGONISTS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 84869998852     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11641120-000000000-00000     Document Type: Article

References (141)

1. Bigal ME, Lipton RB. The epidemiology, burden, and comorbidities of migraine. Neurol Clin 2009 May; 27 (2): 321-34
2. Stewart WF, Wood C, Reed ML, et al., AMPP Advisory Group. Cumulative lifetime migraine incidence in women and men. Cephalalgia 2008 Nov; 28 (11): 1170-8
3. Chugani DC, Niimura K, Chaturvedi S, et al. Increased brain serotonin synthesis in migraine. Neurology 1999 Oct 22; 53 (7): 1473-9
4. Ayata C. Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 2009 Oct; 29 (10): 1095-114
5. Levy D, Burstein R, Strassman AM. Calcitonin generelated peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann Neurol 2005 Nov; 58 (5): 698-705
6. Wolff HG. Headache in the migraine syndrome: headache and other head pain. 2nd ed. New York: Oxford University Press, 1963: 227-385
7. Olesen J, Friberg L, Skyhoj-Olsen T, et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990; 28: 791-8
8. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967 May; 16 (5): 544-52
9. Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl. 9: 23-33
10. Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989 May; 10 (5): 200-4
11. Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache. CNS Drugs 2001; 15 (10): 745-53
12. Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831-5
13. No authors listed. Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group. N Engl J Med 1991 Aug 1; 325 (5): 316-21
14. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000 Dec; 60 (6): 1259-87
15. BelvísR, Pagonabarraga J, Kulisevsky J. Individual triptan selection in migraine attack therapy. Recent Pat CNS Drug Discov 2009 Jan; 4 (1): 70-81
16. Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia 2011 Jul; 31 (9): 1015-22
17. Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-Analysis of 53 trials. Lancet 2001; 358: 1668-75
18. Hu XH, Ng-Mak D, Cady R. Does early migraine treatment shorten time to headache peak and reduce its severity? Headache 2008; 48: 914-20
19. Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analysis of data from three clinical trials. Clin Ther 2000; 22: 1035-48
20. Cady RK, Lipton RB, Hall C, et al. Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000; 40: 792-7
21. Goadsby PJ. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine. Cephalagia 2008; 28 Suppl. 2: 36-41
22. Cady R, Martin V, Mauskop A, et al. Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. Cephalalgia 2007 Sep; 27 (9): 1055-60
23. Mathew NT, Finlayson G, Smith TR, et al., AEGIS Investigator Study Group. Early intervention with almotriptan: results of the AEGIS trial (AXERT early migraine intervention study). Headache 2007 Feb; 47 (2): 189-98
24. Dodick DW. Applying the benefits of the AwM study in the clinic. Cephalalgia 2008; 28 Suppl. 2: 42-9
25. Foley KA, Cady RK, Martin V, et al. Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine. Headache 2005; 45: 538-54
26. Zogenix-, Inc. 2011 Annual Report [online]. Available from URL: http://ir.zogenix.com/phoenix.zhtml?c=220862&p= irol-sec&secCat01.1-rs= 101&secCat01.1-rc=10&control-searchbox=&control-selectgroup= 0[Accessed 2010 Oct 18]
27. Monteith TS, Goadsby PJ. Acute migraine therapy: new drugs and new approaches. Curr Treat Options Neurol 2011 Feb; 13 (1): 1-14
28. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 1-96
29. Blau JN. Adult migraine: the patient observed. In: Blau JN, editor. Migraine: clinical and research aspects. Baltimore (MD): Johns Hopkins University Press, 1987: 3-17
30. Raskin NH, Appenzellar O. Headache. In: Major problems in internal medicine. Vol. 19. Philadelphia (PA): W.B. Saunders, 1980
31. Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982; 22: 66-8
32. Bedell AW, Cady RK, Diamond ML, et al. Patientcentered strategies for effective management of migraine. Springfield (MO): Primary Care Network, 2000
33. Cady R, Schreiber C, Farmer K, et al. Primary headaches: a convergence hypothesis. Headache 2002; 42: 204-16
34. Cady RK, Schreiber CP, Farmer KU. Understanding the patient with migraine: the evolution from episodic headache to chronic neurological disease. Headache 2004; 44: 426-35
35. Headache Classification Committee of the International Headache Society. The international classification of headache disorders. Cephalalgia 2004; 24 Suppl. 1: 1-160
36. Bigal ME, Rapoport AM, Sheftell FD, et al. The International Classification of Headache Disorders revised criteria for chronic migraine: field testing in a headache specialty clinic. Cephalalgia 2007 Mar; 27 (3): 230-4
37. Headache Classification Committee, Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26 (6): 742-6
38. Lipton RB, Chu MK. Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Rev Neurother 2009; 9: 1451-4
39. Bigal ME, Serrano D, Reed M, et al. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 2008; 71: 559-66
40. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008; 48: 1157-68
41. Limmroth V, Katsarava Z, Fritsche G, et al. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002 Oct 8; 59 (7): 1011-4
42. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache center: clinical characteristics and treatment outcomes. Cephalalgia 2004; 24: 483-90
43. Silberstein SD, Olesen J, Bousser M-G, et al. The International Classification of Headache Disorders, 2nd edition (ICHD-II): revision of criteria for 8.2 Medication-overuse headache. Cephalalgia 2005; 25 (6): 460-5
44. Lyseng-Williamson KA, Frampton JE. OnabotulinumtoxinA (BOTOX-): a guide to its use in preventing headaches in adults with chronicmigraine.CNSDrugs 2012 Aug 1; 26 (8): 717-23
45. Buse DC, Manack A, Serrano D, et al. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010 Apr; 81 (4): 428-32
46. Cady R, Farmer K, Dexter JK, et al. Cosensitization of pain and psychiatric comorbidity in chronic daily headache. Curr Pain Headache Rep 2005 Feb; 9 (1): 47-52
47. Waberzinek G, Marková J, Mastík J. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett 2007 Feb; 28 (1): 59-64
48. Newman LC, Lipton RB, Lay CL, et al. A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 1998 Jul; 51 (1): 307-9
49. Lindegaard KF, Ö vrelid L, Sjaastad O. Naproxen in the prevention of migraine attacks: a double-blind placebocontrolled cross-over study. Headache 1980; 20 (2): 96-8
50. Neuman M, Demarez JP, Harmey JL, et al. Prevention of migraine attacks through the use of dihydroergotamine. Int J Clin Pharmacol Res 1986; 6 (1): 11-3
51. Silberstein SD, Merriam GR. Estrogens, progestins, and headache. Neurology 1991 Jun; 41 (6): 786-93
52. Allais G, Bussone G, De Lorenzo C, et al. Naproxen sodium in short-term prophylaxis of pure menstrual migraine: pathophysiological and clinical considerations. Neurol Sci 2007; 28 Suppl. 2: S225-8
53. Luciani R, Carter D, Mannix L, et al. Prevention of migraine during prodrome with naratriptan. Cephalalgia 2000 Mar; 20 (2): 122-6
54. Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 2009 Nov; 29 (11): 1133-48
55. Lipton RB, Stewart WF, Cady R, et al. 2000 Wolfe Award. Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000; 40: 783-91
56. Chakravarty A. How triggers trigger acute migraine attacks: a hypothesis. Med Hypotheses 2010 Apr; 74 (4): 750-3
57. Aurora SK, Wilkinson F. The brain is hyperexcitable in migraine. Cephalalgia 2007; 27 (12): 1442-53
58. Lipton RB. Epilepsy and migraine as comorbid disorders: epidemiologic perspectives. Adv Stud Med 2005; 5 (6E): S649-57
59. Weir GA, Cader MZ. New directions in migraine. BMC Med 2011 Oct 25; 9: 116
60. Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005; 366: 371-7
61. De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump a2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33: 192-6
62. Hansen JM, Thomsen LL, Olesen J, et al. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia 2008 May; 28 (5): 496-505
63. Lance JW. Current concepts of migraine pathogenesis. Neurology 1993 Jun; 43 (6 Suppl 3): S11-5
64. Buzzi MG, Cologno D, Formisano R, et al. Prodromes and the early phase of the migraine attack: therapeutic relevance. Funct Neurol 2005 Oct-Dec; 20 (4): 179-83
65. Bolay H, Reuter U, Dunn AK, et al. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med 2002; 8: 136-42
66. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001; 53: 167-78
67. Bartsch T, Goadsby PJ. Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the duramater. Brain 2003 Aug; 126 Pt 8: 1801-13
68. Bernstein C, Burstein R. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J Clin Neurol 2012 Jun; 8 (2): 89-99
69. Cady RK, Voirin J, Farmer K, et al. Two center, randomized pilot study of migraine prophylaxis comparing paradigms using pre-emptive frovatriptan or daily topir-Amate: research and clinical implications. Headache 2012 May; 52 (5): 749-64
70. Diener HC, Barbanti P, Dahlö f C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2010; 31 (5): 573-84
71. Pfaffenrath V, Fenzl E, Bregman D, et al. Intranasal ketorolac tromethamine (SPRIX) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: safety and efficacy data from a phase II clinical trial. Cephalalgia 2012 Jul; 32 (10): 766-77
72. Fä rkkilä M, Diener HC, Géraud G, et al., COL MIG-202 study group. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012 May; 11 (5): 405-13
73. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 2011 Apr; 51 (4): 507-17
74. Cady RK, Goldstein J, Nett R, et al. A double-blind placebo-controlled pilot study of sublingual feverfew and ginger (LipiGesic-M) in the treatment of migraine. Headache 2011 Jul-Aug; 51 (7): 1078-86
75. Djupesland PG, Docekal P, Czech Migraine Investigators Group. Intranasal sumatriptan powder delivered by novel breath-Actuated bi-directional device for the acute treatment of migraine: a randomized placebo-controlled study. Cephalalgia 2010 Aug; 30 (8): 933-42
76. Kahn K. Cambia (diclofenac potassium for oral solution) in the management of acute migraine. US Neurology 2011; 7 (2): 139-43
77. Cady RK, Aurora SK, Brandes JL, et al. Satisfaction with and confidence in needle-free subcutaneous sumatriptan in patients currently treated with triptans. Headache 2011 Sep; 51 (8): 1202-11
78. Sang CN, Ramadan NM, Wallihan RG, et al. LY293558, a novel AMPA/GluR5 antagonist, is efficacious and welltolerated in acute migraine. Cephalalgia 2004 Jul; 24 (7): 596-602
79. Goldstein J, Smith TR, Pugach N, et al. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache 2012 Oct; 52 (9): 1402-10
80. Landy S, Tepper S, Wein, T, et al. An open-label trial of a sumatriptan auto-injector for migraine [poster]. 54th American Headache Society Annual Scientific Meeting; 2012 Jun 21-24; Los Angeles (CA
81. Goadsby PJ, Hargreaves RJ. Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000; 55: S8-14
82. Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs 2010 Aug 20; 70 (12): 1505-18
83. Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol Sci 2011 Jun; 32 (6): 352-9
84. Neeb L, Meents J, Reuter U. 5-HT(1F) Receptor agonists: a new treatment option for migraine attacks? Neurotherapeutics 2010 Apr; 7 (2): 176-82
85. Pregenzer JF, Alberts GL, Im WB, et al. Differential pharmacology between the guinea-pig and the gorilla 5-HT1D receptor as probed with isochromans (5-HT1D-selective ligands). Br J Pharmacol 1999 May; 127 (2): 468-72
86. Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet 2001 Oct 13; 358 (9289): 1230-4
87. Tfelt-Hansen PC, Olesen J. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain 2012 Jun; 13 (4): 271-5
88. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin generelated peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002 Jun; 54 (2): 233-46
89. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002 Apr 19; 277 (16): 14294-8
90. Arulmani U, Maassenvandenbrink A, Villaló n CM, et al. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004 Oct 1; 500 (1-3): 315-30
91. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372: 2115-23
92. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011; 31: 712-22
93. Ho TW, Olesen J, Dodick DW, et al. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache 2011 Jan; 51 (1): 64-72
94. Olesen J, Diener H, Husstedt I, et al. Calcitonin generelated peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Eng J Med 2004; 350: 1104-10
95. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70: 1304-12
96. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 2009 Sep 22; 73 (12): 970-7
97. Raskin N. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36 (7): 995-7
98. Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc 2011 Oct; 86 (10): 948-55
99. Shrewsbury S, Cook R, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (TEMPO) inhaler. Headache 2008; 48: 355-67
100. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache 2003 Feb; 43 (2): 144-66
101. Masterson CG, Durham PL. DHE repression of ATPmediated sensitization of trigeminal ganglion neurons. Headache 2010 Oct; 50 (9): 1424-39
102. Kori S, Zhang J, Kellerman D, et al. Sustained pain relief with dihydroergotamine in migraine is potentially due to persistent binding to 5-ht(1b) and 5-ht(1d) receptors [poster]. 54th American Headache Society Annual Scientific Meeting; 2012 Jun 21-24; Los Angeles (CA
103. Seybold VS. The role of peptides in central sensitization. Handb Exp Pharmacol 2009; (194): 451-91
104. Dahlö f C, Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan-basic science in relation to migraine treatment. Headache 2012; 52 (4): 707-14
105. Voscopoulos C, Lema M. When does acute pain become chronic? Br J Anaesth 2010 Dec; 105 Suppl. 1: I69-I85
106. Collins S, Sigtermans MJ, Dahan A, et al.NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 2010 Nov; 11 (11): 1726-42
107. Kim Y, Cho HY, Ahn YJ, et al. Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models. Pain 2012 May; 153 (5): 1022-9
108. TorreyPines Therapeutics, Inc. Tezampanel meets primary endpoint in phase IIb clinical trial in acute migraine headache [media release]. 2007 Oct 22 [online]. Available from URL: http://www.drugs.com/clinical-trials/tezam panel-meets-primary-endpoint-phase-iib-clinical-trial-Acutemigraine-headache- 2332.html
109. Newman L, Mannix LK, Landy S, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 2001 Mar; 41 (3): 248-56
110. Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan: a human model for development of migraine drugs. Cephalalgia 1996 Oct; 16 (6): 412-8
111. Olesen J, Jansen-Olesen I. Nitric oxide mechanisms in migraine. Pathol Biol (Paris) 2000 Sep; 48 (7): 648-57
112. Faraci FM, Heistad DD. Regulation of the cerebral circulation: role of endothelium and potassium channels. Physiol Rev 1998 Jan; 78 (1): 53-97
113. Murphy S. Production of nitric oxide by glial cells: regulation and potential roles in the CNS. Glia 2000 Jan 1; 29 (1): 1-13
114. Paakkari I, Lindsberg P. Nitric oxide in the central nervous system. Ann Med 1995 Jun; 27 (3): 369-77
115. Vause CV, Durham PL. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-Activated protein kinase pathways. J Neurochem 2009 Aug; 110 (3): 811-21
116. Høivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia 2010 Dec; 30 (12): 1458-67
117. Van der Schueren BJ, Lunnon MW, Laurijssens BE, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol 2009 Mar; 49 (3): 281-90
118. Sarchielli P, Alberti A, Codini M, et al. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia 2000 Dec; 20 (10): 907-18
119. Vardi J, Flechter S, Alguati A, et al. PGE2 levels in the saliva of common migraineous women. Headache 1983; 23: 59-61
120. Tuca JO, Planas JM, Parellada PP. Increase in PGE2 and TXA2 in the saliva of common migraine patients: action of calcium channel blockers. Headache 1989 Sep; 29 (8): 498-501
121. Durham PL, Vause CV, Derosier F, et al. Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache 2010 May; 50 (5): 844-51
122. Coleman RA, Smith WL, Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 1994 Jun; 46 (2): 205-29
123. Maubach KA, Davis RJ, Clark DE, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 2009 Jan; 156 (2): 316-27
124. Antonova M, Wienecke T, Maubach K, et al. The pharmacological effect of BGC20-1531, a novel prostanoid EP4 receptor antagonist, in the prostaglandin E2 human model of headache. J Headache Pain 2011 Oct; 12 (5): 551-9
125. Rainero I, De Martino P, Pinessi L. Hypocretins and primary headaches: neurobiology and clinical implications. Expert Rev Neurother 2008; 8 (3): 409-16
126. Peyron C, Tighe DK, Van Den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015
127. Piper DC, Upton N, Smith MI, et al. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 2000; 12: 726-30
128. Harris GC, Wimmer M, Aston-Jones G. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 2005; 437: 556-9
129. Bartsch T, Levy MJ, Knight YE, et al. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 2004; 109: 367-78
130. Merck. A study of the safety and efficacy of MK-6096 for migraine prophylaxis in participants with episodic migraine (MK-6096-020) [ClinicalTrials.gov identifier NCT01513291]. US National Institutes of Health, Clin icalTrials.gov [online]. Available from URL: http://clin icaltrials.gov [Accessed 2012 Oct 15]
131. Sumavel-DosePro-. Product information [online]. Available from URL: http://www.sumaveldosepro.com/[Accessed 2012 Oct 15]
132. Brandes JL, Cady RK, Freitag FG, et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 2009 Nov-Dec; 49 (10): 1435-44
133. Smith TR, Goldstein J, Singer R, et al. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache 2012 Apr; 52 (4): 612-24
134. Djupesland PG, Skretting A. Nasal deposition and clearance in man: comparison of a bidirectional powder device and a traditional liquid spray pump. J Aerosol Med Pulm Drug Deliv 2012 Oct; 25 (5): 280-9
135. Cook RO, Shrewsbury SB, Ramadan NM. Reduced adverse event profile of orally inhaled DHE (MAP0004) vs IV DHE: potential mechanism. Headache 2009 Nov-Dec; 49 (10): 1423-34
136. Rapoport AM. The therapeutic future in headache. Neurol Sci 2012 May; 33 Suppl. 1: 119-25
137. Silberstein SD, Young WB, Hopkins MM, et al. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache 2007; 47 (6): 878-85
138. ChangD,Kellermann S,Kori S, et al. Acute inhaled safety of MAP0004: studies in healthy volunteers, smokers, and patients with asthma [poster]. 54th Annual Scientific Meeting of the American Headache Society; 2012 Jun 21-24; Los Angeles (CA)
139. Silberstein S, Tepper S, Brandes J, et al. Randomized, placebo-controlled trial of rofecoxib in the acute treatment of migraine. Neurology 2004 May 11; 62 (9): 1552-7
140. Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002 May; 22 (4): 309-12
141. Aurora SK, Rozen TD, Kori SH, et al. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache 2009 Jun; 49 (6): 826-37